19 Jun 2020 --- Heart health needs to be “more accessible, more understandable, more convenient and easier to keep in balance for consumers globally,” Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health, tells NutritionInsight. Tapping into the lucrative probiotics market, the wholly owned subsidiary of OptiBiotix Health has entered into a non-exclusive distribution agreement with Cambridge Commodities Ltd (CCL) for the UK distribution of LPLDL and CholBiomex3, ProBiotix’s heart health-targeting probiotic ingredient and product, respectively. The fusion of probiotics and heart health is a “completely new category in the UK,” he says.
